Safiyyah Bhatti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Safiyyah Bhatti has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Joffe
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, jefferson.edu
3 shared publications - Lauren Banner
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA
3 shared publications - Neda Nikbakht
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA; Departments of Dermatology, Hematology, and Medical Oncology, Emory University, Atlanta, GA
3 shared publications - Jaanvi Mehta
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, jefferson.edu
2 shared publications - Jenna L. Mandel
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, jefferson.edu
2 shared publications - Anjali Mishra
Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2026 (1) , 5004676
Dabrafenib‐Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is a rare malignancy marked by clonal proliferation of Langerhans cells, with BRAF V600E mutations identified in over 50% of the cases. BRAF inhibitors (BRAFi), such as dabrafenib, have shown efficacy in treating BRAF V600E‐mutant LCH. However, BRAFi therapy is associated with cutaneous adverse effects, including the development of new melanocytic nevi, verrucae, and keratinocyte carcinoma (KC). This case report describes a 78‐year‐old woman with BRAF V600E‐mutant LCH who developed multiple dermatologic side effects following dabrafenib salvage therapy. Seven weeks into treatment, the patient presented with eruptive palmoplantar nevi, verrucae, and a basal cell carcinoma (BCC). Biopsies revealed endophytic verruca vulgaris and acral junctional melanocytic nevus. A previous history of KC and photodamage likely contributed to the development of BCC. Additionally, the patient experienced arthralgias and Dupuytren’s contracture, consistent with known BRAFi side effects. While the cutaneous manifestations observed here have been documented in BRAF V600E‐mutant melanoma, this case is unique in its presentation in LCH patients. This report emphasizes the need for routine dermatologic monitoring and awareness of potential skin malignancies and other side effects in adults undergoing BRAFi therapy for LCH.
- 1 January 2026
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2026 (1) , 5004676
Open AccessDabrafenib‐Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is a rare malignancy marked by clonal proliferation of Langerhans cells, with BRAF V600E mutations identified in over 50% of the cases. BRAF inhibitors (BRAFi), such as dabrafenib, have shown efficacy in treating BRAF V600E‐mutant LCH. However, BRAFi therapy is associated with cutaneous adverse effects, including the development of new melanocytic nevi, verrucae, and keratinocyte carcinoma (KC). This case report describes a 78‐year‐old woman with BRAF V600E‐mutant LCH who developed multiple dermatologic side effects following dabrafenib salvage therapy. Seven weeks into treatment, the patient presented with eruptive palmoplantar nevi, verrucae, and a basal cell carcinoma (BCC). Biopsies revealed endophytic verruca vulgaris and acral junctional melanocytic nevus. A previous history of KC and photodamage likely contributed to the development of BCC. Additionally, the patient experienced arthralgias and Dupuytren’s contracture, consistent with known BRAFi side effects. While the cutaneous manifestations observed here have been documented in BRAF V600E‐mutant melanoma, this case is unique in its presentation in LCH patients. This report emphasizes the need for routine dermatologic monitoring and awareness of potential skin malignancies and other side effects in adults undergoing BRAFi therapy for LCH.
- Open Access
- 6 November 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (1) , 100323
Identifying Subsets of Cancer Patients with an Increased Risk of Developing Cutaneous Melanoma: A Surveillance, Epidemiology, and End Results–Based Analysis
- 6 November 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (1) , 100323
Open AccessIdentifying Subsets of Cancer Patients with an Increased Risk of Developing Cutaneous Melanoma: A Surveillance, Epidemiology, and End Results–Based Analysis
- Open Access
- 13 October 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (20) , 6206-6210
The overlap of skin and blood T-cell clones in early-stage mycosis fungoides
- 13 October 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (20) , 6206-6210
Open AccessThe overlap of skin and blood T-cell clones in early-stage mycosis fungoides